Compositions comprising il-31 and uses thereof

Abstract

A method for treating cancer and/or preventing or reducing metastasis or treating angiogenesis related disorders comprising as the step of administering IL-31 or peptide which is at least about 70%, homologous to the IL-31 sequence as set forth in SEQ ID No. 1.

1 . A method for treating cancer and/or preventing or reducing metastasis comprising the step of administering IL-31 or peptide which is at least about 70%, homologous to the IL-31 sequence as set forth in SEQ ID No. 1, a fused protein comprising IL-31 or peptide which is at least about 70%, homologous to the IL-31 sequence as set forth in SEQ ID No. 1, an agent which up-regulates IL-31, an IL-31 receptor agonist or a complex comprising either IL-31 or peptide which is at least about 70%, homologous to the IL-31 sequence as set forth in SEQ ID No. 1 or a fused protein that comprises IL-31 or peptide which is at least about 70%, homologous to the IL-31 sequence as set forth in SEQ ID No. 1, to a subject in need, thereby treating cancer and/or reducing or preventing metastasis. 
     
     
         2 . A method for treating angiogenesis related disorder comprising the step of administering IL-31 or peptide which is at least about 70%, homologous to the IL-31 sequence as set forth in SEQ ID No. 1, a fused protein comprising IL-31 or peptide which is at least about 70%, homologous to the IL-31 sequence as set forth in SEQ ID No. 1, an agent which up-regulates IL-31, an IL-31 receptor agonist or a complex comprising either IL-31 or peptide which is at least about 70%, homologous to the IL-31 sequence as set forth in SEQ ID No. 1 or a fused protein that comprises IL-31 or peptide which is at least about 70%, homologous to the IL-31 sequence as set forth in SEQ ID No. 1 to a subject in need, thereby treating the angiogenesis related disorder. 
     
     
         3 . A fused protein comprising IL-31 or peptide which is at least about 70%, homologous to the IL-31 sequence as set forth in SEQ ID No. 1. 
     
     
         4 . The fused protein of  claim 3 , wherein said IL-31 to the IL-31 sequence as set forth in SEQ ID No. 1 is attached to a heterologous amino acid sequence. 
     
     
         5 . The fused protein of  claim 4 , wherein said heterologous amino acid sequence comprises an immunoglobulin amino acid sequence. 
     
     
         6 . The fused protein of  claim 5 , wherein the immunoglobulin amino acid sequence comprises IgG. 
     
     
         7 . The fused protein of  claim 3 , wherein the fused protein further comprises a cleavage site for an enzyme. 
     
     
         8 . The fused protein of  claim 7 , wherein the enzyme is trypsin, PSA, MMP-9/2 or cathepsin or any combination thereof. 
     
     
         9 - 14 . (canceled) 
     
     
         15 . A complex comprising IL-31 or a fused protein comprising IL-31 or peptide which is at least about 70%, homologous to the IL-31 sequence as set forth in SEQ ID No. 1 and non-proteinaceous or proteinaceous moiety. 
     
     
         16 . The complex of  claim 15 , wherein the non proteinaceous is polyethylene glycol (PEG) or derivative thereof, polyvinyl pyrrolidone (PVP), divinyl ether, albumin, maleic anhydride copolymer (DIVEMA), polysialic acid (PSA), poly(styrene comaleic anhydride) (SMA), hyaluronic acid (HA), alginic acid (AA), polyhydroxyethyl methacrylate (Poly-HEMA), glyme or polyisopropylacrylamide or any combination thereof. 
     
     
         17 . The complex of  claim 15 , in a form of a liposome or a micelle. 
     
     
         18 - 19 . (canceled) 
     
     
         20 . The method of  claim 1 , wherein the cancer is selected from the group consisting of brain cancer, oropharyngeal cancer, nasopharyngeal cancer, renal cancer, biliary cancer, prostatic cancer, pheochromocytoma, pancreatic islet cell cancer, Li-Fraumeni tumors, thyroid cancer, parathyroid cancer, pituitary tumors, adrenal gland tumors, osteogenic sarcoma tumors, multiple neuroendrcine type I and type II tumors, breast cancer, lung cancer, head & neck cancer, prostate cancer, esophageal cancer, tracheal cancer, skin cancer brain cancer, liver cancer, bladder cancer, stomach cancer, pancreatic cancer, ovarian cancer, uterine cancer, cervical cancer, testicular cancer, colon cancer, rectal cancer and skin cancer. 
     
     
         21 . The method of  claim 2 , wherein the related disorder is selected from the group consisting of cancer, arthritis, rheumatoid arthritis, atherosclerotic plaques, conical graft neovascularization, hypertrophic or keloid scars, proliferative retinopathy, diabetic retinopathy, macular degeneration, age related macular degeneration (AMD), granulation, neovascular glaucoma, uveitis, liver fibrosis, lung fibrosis asthma, Idiopathic Pulmonary Fibrosis (IPF), Myelofibrosis and Primary Sclerosing Cholangitis. 
     
     
         22 . The method  claim 1 , wherein the cancer is hematological malignance selected from the group consisting of multiple myeloma, acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphoblasic leukemia, chronic myeloid leukemia (CML) or mesothieloma.